PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs

PCSK9 has now become an important target to create new classes of lipid-lowering drugs. The prevention of its interaction with LDL receptors allows an increase in the number of these receptors on the surface of the cell membrane of hepatocytes, which leads to an increase in the uptake of cholesterol...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Nikolay Kuzmich, Elena Andresyuk, Yuri Porozov, Vadim Tarasov, Mikhail Samsonov, Nina Preferanskaya, Valery Veselov, Renad Alyautdin
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2022-01-01
Цуврал:	Molecules
Нөхцлүүд:	PCSK9 LDLR antihyperlipidemic therapy lipid-lowering drugs PCSK9 inhibitors
Онлайн хандалт:	https://www.mdpi.com/1420-3049/27/2/434
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!